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Background: Two variants in the gene encoding the cytochrome P450 2C9 enzyme (CYP2C9) are considered the
most significant genetic risk factors associated with bleeding after warfarin prescription. A variant in the vitamin K
epoxide reductase (VKORC1) has been also associated by several studies with warfarin response. Another variant in
the P450 3A5 enzyme (CYP3A5) gene is known to affect the metabolism of many drugs, including tacrolimus.
Findings: We conducted a population genetic study in 148 unrelated healthy Greek-Cypriot volunteers (through
PCR-RFLP assays), in order to determine the frequencies of the above pharmacogenetics variants and to compare
allele frequencies with those in other major ethnic groups. The allele frequencies of CYP2C9*2, CYP2C9*3 and
CYP3A5*3 were found to be 0.162, 0.112 and 0.943 respectively, whereas VKORC1 − 1639A was 0.534. The latter
frequency differs significantly when compared with Caucasians, Asians and Africans (p < 0.001) and is still significant
when compared with the geographically and culturally closely related to Greek-Cypriots, Hellenes of Greece
(p = 0.01). Interestingly ~18% of our population are carriers of four or three risk alleles regarding warfarin sensitivity,
therefore they have a high predisposition for bleeding after taking high or even normal warfarin doses.
Conclusions: Our data show no significant difference in the frequency of CYP2C9 and CYP3A5 allelic variants when
compared to the Caucasian population, but differ significantly when compared with Africans and Asians (p < 0.001).
Also, the frequency of variant VKORC1 − 1639A differs between Greek-Cypriots and every other population we
compared. Finally, about 1/5 Greek-Cypriots carry three or four risk alleles and ~50% of them carry at least two
independent risk alleles regarding warfarin sensitivity, a potentially high risk for over-anticoagulation.
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Background
There are genetic variations in genes encoding for the
hepatic CYP450 metabolizing enzymes that can lead to
undesirable drug reactions or inadequate response to
commonly prescribed doses, either because of reduced
or enhanced enzyme activity, respectively [1]. Testing
for the activity of the CYP450 enzymes and isoforms be-
fore a patient receives a specific medication can provide
valuable information concerning the initial dose. Mo-
lecular genetic testing is advantageous and more cost-* Correspondence: kvoskar@ucy.ac.cy; Deltas@ucy.ac.cy
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distribution, and reproduction in any mediumeffective compared to enzymatic methods due to meth-
odological simplicity.
It is notable that in August 2007, the FDA label for
warfarin, a frequently used anti-coagulant drug, was up-
dated to highlight the benefit of genetic testing to pre-
dict warfarin response. This was renewed on February
2010 (http://www.fda.gov/). Candidate-gene association
studies have identified two genes responsible for the main
proportion of warfarin response: CYP2C9, which codes for
the enzyme cytochrome CYP450 2C9 that metabolizes
S-warfarin [2] and VKORC1, which codes for warfarin’s
target, vitamin K epoxide reductase [3]. CYP2C9*2 (Arg
144 to Cys) and CYP2C9*3 (Ile 359 to Leu) are recognized
as the main CYP2C9 variants in humans, affecting ne-
gatively the enzyme activity [4,5]. In order to avoid high
risk for bleeding, these polymorphisms must be taken intontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Table 1 Genotype distribution of the four pharmacogenetics variants in the Greek-Cypriot population
VKORC1 -1639AG CYP2C9 CYP2C9 CYP3A5
n AA AG GG *1/*1 *1/*2 *2/*2 *1/*1 *1/*3 *3/*3 *1/*1 *1/*3 *3/*3
148 44 70 34 107 34 7 115 33 0 0 17 131
100 29.7% 47.3% 23.0% 72.3% 23.0% 4.7% 77.7% 22.3% 0% 0% 11.5% 88.5%
Table 2 Genotypic combinations of the three genotyped
variants related with warfarin, in 148 Greek-Cypriot
individuals
Genotypic combinations No %
VKORC1 -AA CYP2C9*2/*2 CYP2C9*1/*3 0 0
VKORC1 -AA CYP2C9*2/*2 CYP2C9*1/*1 2**** 1.35
VKORC1 -AA CYP2C9*1/*2 CYP2C9*1/*3 2**** 1.35
VKORC1 -AG CYP2C9*1/*2 CYP2C9*1/*3 2*** 1.35
VKORC1 -AG CYP2C9*2/*2 CYP2C9*1/*1 3*** 2.03
VKORC1 -AA CYP2C9*1/*2 CYP2C9*1/*1 7*** 4.73
VKORC1 -AA CYP2C9*1/*1 CYP2C9*1/*3 10*** 6.76
VKORC1 -AG + GG CYP2C9*1/*1 CYP2C9*1/*3 19 12.84
VKORC1 -AA CYP2C9*1/*1 CYP2C9*1/*1 23 15.54
VKORC1 -AG + GG CYP2C9*1/*2 + *2/*2 CYP2C9*1/*1 25 16.89
VKORC1 -AG + GG CYP2C9*1/*1 CYP2C9*1/*1 55 37.16
SUM 148 100
No CYP2C9*3/*3 genotypes were observed.
****Individuals with four risk alleles (2.70%).
***Individuals with three risk alleles (14.87%).
Hadjipanagi et al. BMC Research Notes 2014, 7:123 Page 2 of 5
http://www.biomedcentral.com/1756-0500/7/123account before warfarin treatment [6]. Warfarin-dosing al-
gorithms that incorporate CYP2C9 and VKORC1 genetic
profile seem to predict pretty accurately the required war-
farin dose for each patient [7,8].
The CYP3A5 gene represents the major extrahepatic
isoform of CYP3A gene family and in association with
CYP3A4 are responsible for the metabolism of over 50%
of all the clinically used drugs [9]. Some studies pay spe-
cial attention at the frequent CYP3A5*3 allele and tacro-
limus dosing [10], a frequently used immunosuppressant
drug. It is recommended that homozygous CYP3A5*3/*3
patients receive roughly a 50% lower initial tacrolimus
dose than patients with at least one wild type CYP3A5*1
allele as a result of the difference observed in oral clear-
ance [10,11].
According to the available bibliography, it is more than
evident that different human populations can differ sig-
nificantly in genetic allelic frequencies for drug meta-
bolism genes [12]. The purpose of the present study was
to investigate for the first time the prevalence of the
most common allelic variants of VKORC1, CYP2C9 and
CYP3A5 in a representative sample of the Greek-Cypriot
population, and to compare these data with existing
published data from other populations.
Methods
Subjects
Genomic DNA isolated from whole peripheral blood
[13] from 148 male healthy unrelated Greek-Cypriot sub-
jects over 20 years old, was used for this study. The po-
pulation of Greek-Cypriots is 660,000 (census of 2011),
therefore the number of 148 individuals represents ad-
equately our population. The subjects were selected
according to their origin, aiming at even geographical
coverage of all the provinces of Cyprus, including moun-
tainous areas, thereby avoiding population stratifica-
tion. We enrolled only male subjects for this study due
to the fact we had more information about their geo-
graphic origin in contrast with females, because of their
participation in another phylogenetics project. The
DNA samples were used after they were anonymized.
Our research project has been approved by the Cyprus
National Bioethics Committee. Informed consent was ob-
tained from all subjects. Research carried out on volun-
teers of this study was in compliance with the Helsinki
Declaration.Molecular genetic analysis
In this study we directly tested our sample group only for
the four following genetic variants: VKORC1 g.-1639G/A,
CYP2C9*2, CYP2C9*3 and CYP3A5*3. We did not test
specifically for the wild type CYP2C9*1 allele, the fre-
quency of which was inferred from the absence of the two
variants tested. The genetic polymorphisms were geno-
typed by PCR-RFLP assays. Details of the methods regard-
ing the VKORC1 g.-1639G/A, CYP2C9*2 and CYP3A5*3
polymorphisms are described elsewhere [14-16]. For the
CYP2C9*3 polymorphism, the following primers were de-





The forward primer was modified by substitution of the
fourth nucleotide from the 3’ end, from A to G (italics and
bold), so that upon amplification a restriction recognition
site for BanI is created. The digestion products were
analyzed by electrophoresis on 3.5% agarose gels. The
CYP2C9*3 allele is represented by the 225 bp and 31 bp
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256 bp band.
Statistical analysis
Comparison of population allele frequencies was per-
formed through Pearson chi-square test, using SPSSv.15
statistical package (IBM, USA). The significance level,
alpha, was set to 0.05. Hardy-Weinberg equilibrium was
tested for all the analyzed polymorphisms through an
Excel based application (Microsoft Office 2007).
Results and discussion
Genotypic frequencies for the tested pharmacogenetics
variants in our population are tabulated in Table 1. The
genotypic frequencies for each variant are in Hardy-
Weinberg equilibrium. All the tested Greek-Cypriots areTable 3 Allele frequencies of the four studied pharmacogeneti




















Hellenes from Greece 656 44.40%
(P = 0.010)
566
In parenthesis: p-value after comparison with the Greek-Cypriot frequencies.carriers of the CYP3A5*3 allele (no homozygous wild-
type CYP3A5*1/*1 were found), which is responsible for
reduced tacrolimus clearance, while 88.5% of them are
homozygous CYP3A5*3/*3 (Table 1). These frequencies
are very similar with those for the Hellenic population in
Greece and generally with those for the Caucasian popu-
lation [12,17]. We paid special attention at genotypic
combinations for the three genotyped warfarin related
genes (Table 2). We believe that clinicians in Cyprus have
to take seriously into account that ~18% of the Greek-
Cypriot population they serve are carriers of four or three
risk alleles and about 50% carry at least two risk alleles,
predisposing for bleeding after taking high warfarin doses.
The combinatorial frequency of CYP2C9 and VKORC1
genotypes in the target population appears higher than ex-
pected based on individual genotypes, but we do not havec variants in Cyprus and comparison with other populations
39A CYP2C9*2 CYP2C9*3 CYP3A5*3 Reference























12.90% 8.13% 94.35% [17]
(P = 0.183) (P = 0.144) (P = 0.957)
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six or five risk alleles were not detected. Interestingly,
we found that 2.7% of subjects in our population sample
are simultaneously carriers for the three tested variants
(Table 2), a frequency that is exactly the same with what is
reported in Jewish populations [18].
It has been proven that CYP2C9*2 and *3 cause a re-
duction in S-warfarin clearance (10-fold variation ob-
served from CYP2C9*11 to CYP2C9*33) activity (*1/*1 >
*1/*2 > *1/*3 > *2/*2 > *2/*3 > *3/*3). The effect of the
CYP2C9*3/*3 genotype is the most severe one with clea-
rance of S-warfarin being 10% of the wild type genotype
[19]. VKORC1 encoded enzyme interacts with warfarin,
so the enzyme levels can affect sensitivity to warfarin.
Jorgensen et al. [20], reviewed recently almost all the
available bibliography and found that CYP2C9*3 and
VKORC1 variants are significant for warfarin dose deter-
mination for most ethnic populations [20]. Sconce et al.
[7] showed clearly (giving also a useful algorithm for
warfarin dose determination) that the three significant
variants of the aforementioned genes have additive
properties [7].
In conclusion, it is evident through population specific
studies, like the one we present here, that pharmacogen-
etics allele frequencies can differ significantly in different
sub-populations. The results of our study compare well
to those of other Caucasian populations, but with some
notable differences, like the increased frequency of the
VKORC1-1639A allele (Table 3). Allele frequencies bet-
ween the six provinces of Cyprus show high similarity
(Table 3). We must have in mind that the Greek-Cypriot
population used to be isolated and small, and therefore
susceptible to migratory waves and genetic drift phe-
nomena. Even comparing with the Greek population
of Greece, that we are closely related (geographically
and culturally), there are still some significant differ-
ences (Table 3). This fact underlines the necessity for
population-specific allelic frequency studies, since these
determinations can be helpful for the prescribing clini-
cians and their patients.
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